Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $5.00 at Bank of America

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target lowered by analysts at Bank of America from $6.00 to $5.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s target price would suggest a potential upside of 56.99% from the stock’s current price.

A number of other research analysts have also recently weighed in on CATX. Piper Sandler lowered their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.56.

Perspective Therapeutics Trading Up 2.7%

Shares of NYSEAMERICAN:CATX traded up $0.09 during midday trading on Friday, hitting $3.19. The company had a trading volume of 588,403 shares, compared to its average volume of 2,325,881. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16. The company has a fifty day moving average of $3.08 and a two-hundred day moving average of $3.94.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%. Sell-side analysts forecast that Perspective Therapeutics will post -1.07 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in shares of Perspective Therapeutics by 391.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after purchasing an additional 358,540 shares during the last quarter. Avidity Partners Management LP increased its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. Yu Fan bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at approximately $4,401,000. Seven Fleet Capital Management LP purchased a new stake in Perspective Therapeutics during the 1st quarter valued at $1,581,000. Finally, Ally Bridge Group NY LLC bought a new stake in Perspective Therapeutics in the first quarter worth $3,864,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics News Summary

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised its 2026 loss estimates: Analyst K. Dolliver now expects a loss of $0.25 per share for the third quarter, $0.26 for the fourth quarter and $0.99 for full-year 2026, compared with previous estimates of $0.32, $0.36 and $1.23, respectively. Smaller projected losses may signal improved expectations for operating performance and could support CATX shares.
• Neutral Sentiment: Losses are still expected through 2027. Brookline forecasts quarterly losses of $0.26, $0.27, $0.30 and $0.32 for the first four quarters of 2027, totaling a projected $1.14 loss for the year. The estimates highlight that Perspective Therapeutics remains an early-stage, loss-making biotechnology company, with future results dependent on clinical and commercial progress.
• Negative Sentiment: Piper Sandler lowered its expectations for the stock price, indicating a less favorable near-term view of CATX’s valuation. The available report does not provide the revised target or the specific reasons for the change. Piper Sandler Has Lowered Expectations for Perspective Therapeutics Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.